Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance

被引:107
作者
Chung, Peter [1 ,2 ]
Daugaard, Gedske [3 ]
Tyldesley, Scott [4 ]
Atenafu, Eshetu G. [5 ]
Panzarella, Tony [5 ]
Kollmannsberger, Christian [4 ]
Warde, Padraig [1 ,2 ]
机构
[1] Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[3] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark
[4] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[5] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON M5G 2M9, Canada
关键词
Prognostic model; stage I seminoma; surveillance; GERM-CELL CANCER; TESTICULAR SEMINOMA; EUROPEAN CONSENSUS; MANAGEMENT; DIAGNOSIS;
D O I
10.1002/cam4.324
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A prognostic model for relapse risk in stage I seminoma managed by surveillance after orchiectomy has been developed but has not been independently validated. Individual data on 685 stage I seminoma surveillance patients managed between 1998 and 2005 at three cancer centers were retrospectively analyzed. Variables including age and pathology of the primary tumor: small vessel invasion, tumor size, and invasion of rete testis were analyzed. Specifically median tumor size and rete testis invasion was tested to evaluate the performance of the published model. Median follow-up was 3.85 years (0.1-10.29), 88 patients relapsed and 5-year relapse-free rate was 85%. In univariate analysis, median tumor size (< 3 cm vs. >= 3 cm) was associated with increased risk of relapse but rete testis invasion was not, nor was age and small vessel invasion. In multivariable analysis, tumor size above median (cutpoint of 3 cm) was a predictor for relapse, HR 1.87 (95% CI 1.15, 3.06), whereas rete testis invasion HR 1.36, (95% CI 0.81, 2.28) was not statistically significant. The 3-year relapse risk based on the primary tumor size alone increased from 9% for 1 cm primary tumor to 26% for 8 cm tumor. A clinically useful, highly discriminating prognostic model remains elusive in stage I seminoma surveillance as we were unable to validate the previously developed model. However, primary tumor size retained prognostic importance and a scale of relapse risk based on the unit increment of tumor size was developed to help guide patients and clinicians in decision making.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 19 条
[1]   Risk-adapted management for patients with clinical stage I seminoma:: The second Spanish germ cell cancer cooperative group study [J].
Aparicio, J ;
Germà, JR ;
del Muro, XG ;
Maroto, P ;
Arranz, JA ;
Sáenz, A ;
Barnadas, A ;
Dorca, J ;
Gumà, J ;
Olmos, D ;
Bastús, R ;
Carles, J ;
Almenar, D ;
Sánchez, M ;
Paz-Ares, L ;
Satrústegui, JJ ;
Mellado, B ;
Balil, A ;
López-Brea, M ;
Sánchez, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8717-8723
[2]   Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study [J].
Aparicio, Jorge ;
Maroto, Pablo ;
Garcia del Muro, Xavier ;
Guma, Josep ;
Sanchez-Munoz, Alfonso ;
Margeli, Mireia ;
Domenech, Montserrat ;
Bastus, Roma ;
Fernandez, Antonio ;
Lopez-Brea, Marta ;
Terrassa, Josefa ;
Meana, Andres ;
Martinez del Prado, Purificacion ;
Sastre, Javier ;
Satrustegui, Juan J. ;
Girones, Regina ;
Robert, Lidia ;
Germa, Jose R. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) :4677-4681
[3]   Barriers to the Implementation of Surveillance for Stage I Testicular Seminoma [J].
Arvold, Nils D. ;
Catalano, Paul J. ;
Sweeney, Christopher J. ;
Hoffman, Karen E. ;
Nguyen, Paul L. ;
Balboni, Tracy A. ;
Fossa, Sophie D. ;
Travis, Lois B. ;
Beard, Clair J. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (02) :383-389
[4]   Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer [J].
Beyer, J. ;
Albers, P. ;
Altena, R. ;
Aparicio, J. ;
Bokemeyer, C. ;
Busch, J. ;
Cathomas, R. ;
Cavallin-Stahl, E. ;
Clarke, N. W. ;
Classen, J. ;
Cohn-Cedermark, G. ;
Dahl, A. A. ;
Daugaard, G. ;
De Giorgi, U. ;
De Santis, M. ;
De Wit, M. ;
De Wit, R. ;
Dieckmann, K. P. ;
Fenner, M. ;
Fizazi, K. ;
Flechon, A. ;
Fossa, S. D. ;
Germa Lluch, J. R. ;
Gietema, J. A. ;
Gillessen, S. ;
Giwercman, A. ;
Hartmann, J. T. ;
Heidenreich, A. ;
Hentrich, M. ;
Honecker, F. ;
Horwich, A. ;
Huddart, R. A. ;
Kliesch, S. ;
Kollmannsberger, C. ;
Krege, S. ;
Laguna, M. P. ;
Looijenga, L. H. J. ;
Lorch, A. ;
Lotz, J. P. ;
Mayer, F. ;
Necchi, A. ;
Nicolai, N. ;
Nuver, J. ;
Oechsle, K. ;
Oldenburg, J. ;
Oosterhuis, J. W. ;
Powles, T. ;
Rajpert-De Meyts, E. ;
Rick, O. ;
Rosti, G. .
ANNALS OF ONCOLOGY, 2013, 24 (04) :878-888
[5]   Management of Stage I Seminomatous Testicular Cancer: a Systematic Review [J].
Chung, P. ;
Mayhew, L. A. ;
Warde, P. ;
Winquist, E. ;
Lukka, H. .
CLINICAL ONCOLOGY, 2010, 22 (01) :6-16
[6]   Stage I Seminoma: Adjuvant Treatment is Effective but is it Necessary? [J].
Chung, Peter ;
Warde, Padraig .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (03)
[7]  
Fosså SD, 2010, CANCER OF THE TESTIS, P275, DOI 10.1007/978-1-84800-370-5_20
[8]   Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients [J].
Kamba, Tomomi ;
Kamoto, Toshiyuki ;
Okubo, Kazutoshi ;
Teramukai, Satoshi ;
Kakehi, Yoshiyuki ;
Matsuda, Tadashi ;
Ogawa, Osamu .
INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (12) :980-987
[9]   Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies [J].
Kollmannsberger, C. ;
Tyldesley, S. ;
Moore, C. ;
Chi, K. N. ;
Murray, N. ;
Daneshmand, S. ;
Black, P. ;
Duncan, G. ;
Hayes-Lattin, B. ;
Nichols, C. .
ANNALS OF ONCOLOGY, 2011, 22 (04) :808-814
[10]  
Ramakrishnan S, 1992, Clin Oncol (R Coll Radiol), V4, P284, DOI 10.1016/S0936-6555(05)81100-8